Drug intelligence / Profile preview

methotrexate + sulfasalazine + hydroxychloroquine + prednisolone

Development stage: Unknown
Lead developer: Pfizer
Modality: Small Molecules
Administration: Oral, Subcutaneous, Intramuscular

Overview

A combination therapy consisting of three disease-modifying antirheumatic drugs (DMARDs) - methotrexate, sulfasalazine, and hydroxychloroquine - plus the corticosteroid prednisolone. This combination is used primarily for treating rheumatoid arthritis and other inflammatory autoimmune conditions. The triple DMARD combination provides comprehensive immunomodulation while prednisolone offers rapid symptom relief during the initial treatment period before the DMARDs reach full effectiveness. In clinical practice, prednisolone is often tapered off after several weeks to minimize long-term side effects.

Other names: ACT regimenNORD-STAR ACT armActive Conventional Therapy (NORD-STAR)

Targets

GR (Glucocorticoid receptor)DHFR (Dihydrofolate reductase)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)

Beyond the preview

Go deeper on methotrexate + sulfasalazine + hydroxychloroquine + prednisolone.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on methotrexate + sulfasalazine + hydroxychloroquine + prednisolone.

Explore the full profile